GlassScriptPhysician profile
Pujan Patel
NPI 1518351873
$66,497.45
in general payments reported to CMS, 2019-2025
21 companies · $3,296 in 2025
The $3,296 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2022: $948 · 2023: $25K · 2024: $36K · 2025: $3,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $45K · Food and Beverage: $11K · Travel and Lodging: $9,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $44,669.00 |
| Food and Beverage | $10,909.43 |
| Travel and Lodging | $9,544.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $56,522.02 | 2023-2025 | Barostim Neo System |
| Abbott Laboratories | $5,954.69 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Thoratec Heartmate II, Lvas Implant Kit |
| Abiomed | $1,318.09 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $921.08 | 2024-2025 | |
| Pfizer INC. | $422.87 | 2019-2025 | |
| Daxor Corporation | $413.58 | 2023-2024 | Bva-100 |
| Impulse Dynamics (USA) INC. | $173.45 | 2024 | Optimizer |
| Paragonix Technologies, INC. | $160.04 | 2024 | |
| Kestra Medical Technology Services, INC. | $136.36 | 2023 | Assure Wcd |
| Merck Sharp & Dohme LLC | $130.69 | 2023 | Verquvo |
| Medtronic Vascular, INC. | $119.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $48.28 | 2024 | Camzyos |
| American Regent | $24.93 | 2024 | Injectafer |
| Cardiac Dimensions, INC. | $24.83 | 2023 | |
| Briohealth Solutions, INC. | $21.57 | 2025 | Briovad |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.34 | 2022 | |
| Scpharmaceuticals INC. | $18.73 | 2024 | |
| Alnylam Pharmaceuticals INC. | $17.82 | 2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $17.75 | 2024 | Farxiga |
| Daiichi Sankyo INC. | $17.15 | 2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $15.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pujan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.